Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Sigilon Therapeutics, Inc. | sgtx-20210331ex31236b807.htm |
| EX-31.1 - EX-31.1 - Sigilon Therapeutics, Inc. | sgtx-20210331ex3110efe69.htm |
| 10-Q - 10-Q - Sigilon Therapeutics, Inc. | sgtx-20210331x10q.htm |
Exhibit 32.1
CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Quarterly Report on Form 10-Q of Sigilon Therapeutics, Inc. (the “Company”) for the quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the company, hereby certifies, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that to the best of his knowledge:
(1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 10, 2021 | By: | /s/ Rogerio Vivaldi Coelho, M.D. | |
Rogerio Vivaldi Coelho, M.D. |
Date: May 10, 2021 | By: | /s/ Glenn Reicin | |
Glenn Reicin |